Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial
Clicks: 445
ID: 274575
1997
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
30.0
/100
232 views
232 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Transdermal nicotine administered at the highest tolerated dosage (< or = 22 mg/d) for 4 weeks is efficacious for controlling clinical manifestations of mildly to moderately active ulcerative colitis.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (26 words).
Try re-searching for a better abstract.
| Reference Key |
wj1997annalstransdermal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Sandborn WJ;Tremaine WJ;Offord KP;Lawson GM;Petersen BT;Batts KP;Croghan IT;Dale LC;Schroeder DR;Hurt RD;; |
| Journal | annals of internal medicine |
| Year | 1997 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Administration
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
research support
non-u.s. gov't
adult
female
male
adolescent
aged
middle aged
Remission Induction
Clinical Trial
Randomized Controlled Trial
Double-Blind Method
placebos
Colitis
Ulcerative / drug therapy*
cutaneous
dermatitis
ulcerative / blood
w j sandborn
pmid:9054280
doi:10.7326/0003-4819-126-5-199703010-00004
w j tremaine
r d hurt
cotinine / blood
contact / etiology
nausea / chemically induced
nicotine / administration & dosage*
nicotine / adverse effects
nicotine / blood
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.